JDP is reluctant to speculate publicly.But speculation abhors a...

JDP is reluctant to speculate publicly.

But speculation abhors a vacuum.

My SPECULATION repeat SPECULATION is:
The UON has already started a quick and cheap in-vitro check on human heart cells (HCMs) to see if bisantrene protects the HCMs in vitro against the direct cardiotoxity of the 15 drugs identified in the 15 February 2024 published study which JDP found and kindly announced in a PS HC post which RAC is studiously ignoring. (Note that HC software doesn't cater for identifying PS posts - they think that only companies make PS announcements).
Bisantrene has already demonstrated CPACS with two unrelated classes of drugs. For the unannounced preclinical currently underway, only the CP aspect is relevant.
When the results of this follow-on preclinical study are published, RAC will ignore them for two reasons:
* IP considerations
* because, if they were acknowledged by RAC, bisantrene's TAM would become even harder to believe than it already is and the Triangle report would be downramping.
However a RAC shareholder will find the journal article and post a PS link in this thread.